We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Use baricitinib with caution in patients with diverticular disease and in those concomitantly treated with medications associated with an increased risk of diverticulitis.
Aceclofenac is now contraindicated in patients with certain established cardiovascular diseases.
Public Assessment Report on our review of epidemiological data for cardiovascular safety.
Update of data on musculoskeletal conditions and services for local populations in England.
Updated indicators relevant to older people and healthy ageing.
Projects granted during 2015 that have a primary purpose of translational and applied research: human immune disorders.
Employment Tribunal decision.
Risk of serious side effects on fertility, the liver, kidneys, immune system, blood, and heart.
PHE has launched the musculoskeletal diseases profiles, providing data on musculoskeletal conditions and services for local populations in England.
Employment Tribunal decision
Onsenal▼ (celecoxib) is no longer approved in Europe for the reduction of intestinal polyps in familial adenomatous polyposis (FAP).
Guidance on the cardiovascular safety of Cox-2 inhibitors and NSAIDs and further reading.
Please be vigilant as life-threatening errors may occur
Fluoroquinolones should only be used after careful benefit-risk assessment and after consideration of other therapeutic options in patients at risk for heart valve regurgitation (incompetence).
Letters were sent about Xeljanz▼ (tofacitinib), ranitidine, Nulojix (belatacept), fluoroquinolone antibiotics, Genvoya▼, Stribild▼, Tybost, and belimumab (Benlysta▼). Drug alerts were issued about Accord losartan potassium c…
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).